Format

Send to

Choose Destination
Nat Immunol. 2012 Apr 18;13(5):423-7. doi: 10.1038/ni.2264.

Lessons learned from HIV-1 vaccine trials: new priorities and directions.

Author information

1
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, UK. andrew.mcmichael@ndm.ox.ac.uk

Erratum in

  • Nat Immunol. 2013 Apr;14(4):413.

Abstract

A vaccine against human immunodeficiency virus (HIV) seems to be on the horizon. Correlates of risk of infection for [corrected] the RV144 vaccine trial have been found. There is understanding of what makes HIV envelope-specific antibodies broadly neutralizing and new T cell vaccine approaches can overcome virus variability.

PMID:
22513323
PMCID:
PMC3652652
DOI:
10.1038/ni.2264
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center